Histogenics Corporation (HSGX) Downgraded by Zacks Investment Research
Zacks Investment Research downgraded shares of Histogenics Corporation (NASDAQ:HSGX) from a buy rating to a hold rating in a research report released on Friday. They currently have $2.00 target price on the biotechnology company’s stock.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
A number of other analysts have also issued reports on HSGX. HC Wainwright set a $4.00 price target on Histogenics Corporation and gave the stock a buy rating in a research note on Saturday, May 13th. Canaccord Genuity reissued a buy rating and issued a $4.00 price target on shares of Histogenics Corporation in a research note on Friday, August 11th. Finally, ValuEngine lowered Histogenics Corporation from a sell rating to a strong sell rating in a research note on Monday, August 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. Histogenics Corporation presently has a consensus rating of Hold and an average price target of $5.25.
Shares of Histogenics Corporation (NASDAQ:HSGX) opened at 1.86 on Friday. The stock’s market capitalization is $41.83 million. The company has a 50-day moving average of $1.84 and a 200 day moving average of $1.75. Histogenics Corporation has a one year low of $1.45 and a one year high of $4.47.
Histogenics Corporation (NASDAQ:HSGX) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. During the same period last year, the business earned ($0.61) earnings per share. Equities research analysts forecast that Histogenics Corporation will post ($1.09) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/05/histogenics-corporation-hsgx-downgraded-by-zacks-investment-research.html.
An institutional investor recently raised its position in Histogenics Corporation stock. Sabby Management LLC raised its position in Histogenics Corporation (NASDAQ:HSGX) by 15.9% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,095,422 shares of the biotechnology company’s stock after purchasing an additional 150,531 shares during the quarter. Sabby Management LLC owned 5.31% of Histogenics Corporation worth $1,895,000 at the end of the most recent quarter. Institutional investors and hedge funds own 50.08% of the company’s stock.
Histogenics Corporation Company Profile
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related stocks with our FREE daily email newsletter.